Small Cap H1N1 Biotech Players Mentioned on Bloomberg TV Print E-mail
By Staff and Wire Reports   
Friday, 25 September 2009 04:50

Crystal Research Associates’ chief executive officer and cofounder, Jeffrey Kraws, was interviewed by Bloomberg Television on Thursday discussing some of the issues facing biotech companies and their role in the H1N1 flu pandemic.

During the segment, Mr. Kraws noted recent advances that have been made in vaccine and treatment technologies, including those at CEL-SCI Corporation (AMEX:CVN), Generex Biotechnology (NASDAQ:GNBT), and Unilife Medical Solutions Limited (ASX:UNI). Video of the segment appears below.

Last week, CEL-SCI announced that the U.S. Food and Drug Administration (FDA) had indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.





"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter